US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hemostemix Inc

0.0573

0.0000

Volume:- -

Turnover:- -

Market Cap:11.19M

PE:-2.74

High:0.0573

Open:0.0573

Low:0.0573

Close:0.0573

52wk High:0.1410

52wk Low:0.0500

Shares:195.25M

Float Shares:141.12M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0209

EPS(LYR):-0.0230

ROE:441.27%

ROA:-327.22%

PB:-4.43

PE(LYR):-2.50

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Hemostemix Inc

Exchange:

OTCQB

Establishment Date:

- -

Employees:

- -

Office Location:

707-7th Avenue SW,Suite 1150,Calgary,Alberta,Canada

Website:

http://www.hemostemix.com

Zip Code:

T2P 3H6

Phone:

- -

Fax:

- -

Introduction:

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HMTXF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HMTXF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HMTXF\",,,,,undefined,":{"symbol":"HMTXF","market":"US","secType":"STK","nameCN":"Hemostemix Inc","latestPrice":0.0573,"timestamp":1771876800000,"preClose":0.0573,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":141116391,"shares":195253383,"eps":-0.0208938,"marketStatus":"Trading","change":0,"latestTime":"02-23 15:00:00 EST Delay","open":0.0573,"high":0.0573,"low":0.0573,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.0208938,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.0573,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HMTXF\",,,,,undefined,":{"symbol":"HMTXF","floatShares":141116391,"roa":"-327.22%","roe":"441.27%","lyrEps":-0.022965,"shares":195253383,"dividePrice":0,"high":0.0573,"amplitude":0,"preClose":0.0573,"low":0.0573,"week52Low":0.05,"pbRate":"-4.43","week52High":0.141,"institutionHeld":0,"latestPrice":0.0573,"eps":-0.0208938,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.0208938,"open":0.0573,"prevYearClose":0.0625,"prevWeekClose":0.0573,"prevMonthClose":0.0686,"prevQuarterClose":0.0625,"fiveDayClose":0.0662,"twentyDayClose":0.0686,"sixtyDayClose":0.065},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HMTXF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-29","symbol":"HMTXF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714363200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-29","symbol":"HMTXF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1701234000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-09-26","symbol":"HMTXF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1664164800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2020-12-30","symbol":"HMTXF","defaultRemindTime":1609338600000,"type":"split","dateTimestamp":1609304400000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HMTXF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HMTXF\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":240304994,"address":"707-7th Avenue SW,Suite 1150,Calgary,Alberta,Canada","zipCode":"T2P 3H6"},"stockCompanyDetail":{"websiteUrl":"http://www.hemostemix.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.7043},{"period":"6month","weight":-0.722},{"period":"1year","weight":-0.8284},{"period":"ytd","weight":-0.7377}],"description":"Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","exchange":"OTCQB","name":"Hemostemix Inc","nameEN":"Hemostemix Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"HMTXF\",market:\"US\",,,undefined,":null}}